Genetic prognostic and predictive markers in colorectal

Nature Reviews Cancer

9, 489-499

Citation Report

#	ARTICLE	IF	CITATIONS
1	Pharmacogenomic Discovery Using Cell-Based Models. Pharmacological Reviews, 2009, 61, 413-429.	7.1	109
3	Anaplastic Glioma: How to Prognosticate Outcome and Choose a Treatment Strategy. Journal of Clinical Oncology, 2009, 27, 5861-5862.	0.8	48
4	The applications of pharmacogenetics to prescribing: what is currently practicable?. Clinical Medicine, 2009, 9, 493-495.	0.8	7
5	The Forest and the Trees: Pathways and Proteins As Colorectal Cancer Biomarkers. Journal of Clinical Oncology, 2009, 27, 5866-5867.	0.8	9
6	Integrating complex genomic datasets and tumour cell sensitivity profiles to address a 'simple' question: which patients should get this drug?. BMC Medicine, 2009, 7, 78.	2.3	3
7	Impact of tumour genotyping on cancer management. Journal of Cellular and Molecular Medicine, 2009, 13, 4089-4089.	1.6	1
8	Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut, 2009, 58, 357-365.	6.1	289
9	Translating the cancer genome into clinically useful tools and strategies. DMM Disease Models and Mechanisms, 2009, 2, 426-429.	1.2	12
10	EGFR(S) Inhibitors in the Treatment of Gastro-Intestinal Cancers: Whats New?. Current Drug Targets, 2010, 11, 682-698.	1.0	12
11	Role of CDK8 and Î²-catenin in colorectal adenocarcinoma. Oncology Reports, 2010, 24, .	1.2	20
12	Relating biomarkers to efficacy and the efficacy curve: a review of EGFR therapies in oncology. Personalized Medicine, 2010, 7, 19-31.	0.8	0
13	Molecular Markers in the Treatment of Metastatic Colorectal Cancer. Cancer Journal (Sudbury, Mass) Tj ETQq1 1 0.784314 rgBT /Ove	1.0	77
14	Nervous system tumors associated with familial tumor syndromes. Current Opinion in Neurology, 2010, 23, 583-591.	1.8	21
16	Human variation databases. Database: the Journal of Biological Databases and Curation, 2010, 2010, baq015-baq015.	1.4	19
17	Experiences with the SELDI-TOF Method for the Detection of the Diabetes Associated Antigen GAD 65 in the Peripheral Blood of Patients with Diabetes and Inflammation. Pteridines, 2010, 21, 22-28.	0.5	0
18	The Effects of Obesity and Obesity-Related Conditions on Colorectal Cancer Prognosis. Cancer Control, 2010, 17, 52-57.	0.7	72
21	Strong association between cancer and genomic instability. Radiation and Environmental Biophysics, 2010, 49, 125-131.	0.6	49
22	'OMICS': state of the art in vitro techniques employed in surgical research. European Surgery - Acta Chirurgica Austriaca, 2010, 42, 127-133.	0.3	2

#	Article	IF	Citations
23	TGFB1 509 C/T polymorphism and colorectal cancer risk: a meta-analysis. Medical Oncology, 2010, 27, 1324-1328.	1.2	29
24	Biomarkers in colorectal cancer: the future is getting closer. Clinical and Translational Oncology, 2010, 12, 241-242.	1.2	2
25	PrÃ¤diktive und prognostische genetische Biomarker. Wiener Klinische Wochenschrift Education, 2010, 5, 49-71.	0.0	0
26	Mass spectrometry protein expression profiles in colorectal cancer tissue associated with clinico-pathological features of disease. BMC Cancer, 2010, 10, 410.	1.1	8
27	Expression of CIAPIN1 in human colorectal cancer and its correlation with prognosis. BMC Cancer, 2010, 10, 477.	1.1	17
28	Allelotyping identification of genomic alterations in rectal chromosomally unstable tumors without preoperative treatment. BMC Cancer, 2010, 10, 561.	1.1	1
29	Analysis of post-operative changes in serum protein expression profiles from colorectal cancer patients by MALDI-TOF mass spectrometry: a pilot methodological study. World Journal of Surgical Oncology, 2010, 8, 33.	0.8	13
30	Therapeutic modulation of k-ras signaling in colorectal cancer. Drug Discovery Today, 2010, 15, 502-516.	3.2	38
31	<i>MDM2</i> gene amplification in colorectal cancer is associated with disease progression at the primary site, but inversely correlated with distant metastasis. Genes Chromosomes and Cancer, 2010, 49, 620-629.	1.5	12
32	dbCPCO: a database of genetic markers tested for their predictive and prognostic value in colorectal cancer. Human Mutation, 2010, 31, 901-907.	1.1	19
33	CDK8 expression in 470 colorectal cancers in relation to Î²â€catenin activation, other molecular alterations and patient survival. International Journal of Cancer, 2010, 126, 2863-2873.	2.3	88
34	Combined analysis of specific <i>KRAS</i> mutation, <i>BRAF</i> and microsatellite instability identifies prognostic subgroups of sporadic and hereditary colorectal cancer. International Journal of Cancer, 2010, 127, 2569-2575.	2.3	99
35	Restoration of DNAâ€binding and growthâ€suppressive activity of mutant forms of p53 via a PCAFâ€mediated acetylation pathway. Journal of Cellular Physiology, 2010, 225, 394-405.	2.0	33
36	A Gene Expression Signature for Chemoradiosensitivity of Colorectal Cancer Cells. International Journal of Radiation Oncology Biology Physics, 2010, 78, 1184-1192.	0.4	82
37	Oncogenic KRAS sensitises colorectal tumour cells to chemotherapy by p53-dependent induction of Noxa. British Journal of Cancer, 2010, 102, 1254-1264.	2.9	22
38	Quantitative expression analysis and prognostic significance of L-DOPA decarboxylase in colorectal adenocarcinoma. British Journal of Cancer, 2010, 102, 1384-1390.	2.9	50
39	Strategies and challenges for the next generation of therapeutic antibodies. Nature Reviews Immunology, 2010, 10, 345-352.	10.6	742
40	The Human Transcriptome. , 2010, , 89-103.		2

#	ARTICLE	IF	CITATIONS
41	Biomarker-Based Prediction of Response to Therapy for Colorectal Cancer. American Journal of Clinical Pathology, 2010, 134, 478-490.	0.4	69
42	Defective Mismatch Repair in Colon Cancer: A Prognostic Or Predictive Biomarker?. Journal of Clinical Oncology, 2010, 28, 3210-3212.	0.8	29
43	Molecular circuits of solid tumors: prognostic and predictive tools for bedside use. Nature Reviews Clinical Oncology, 2010, 7, 367-380.	12.5	94
44	Specific Alterations of MicroRNA Transcriptome and Global Network Structure in Colorectal Carcinoma after Cetuximab Treatment. Molecular Cancer Therapeutics, 2010, 9, 3396-3409.	1.9	95
45	Microsatellite Instability Detection by High-Resolution Melting Analysis. Clinical Chemistry, 2010, 56, 1750-1757.	1.5	35
46	The Role of the CpG Island Methylator Phenotype in Colorectal Cancer Prognosis Depends on Microsatellite Instability Screening Status. Clinical Cancer Research, 2010, 16, 1845-1855.	3.2	155
47	Oncogenic engagement of the Met receptor is sufficient to evoke angiogenic, tumorigenic, and metastatic activities in rat intestinal epithelial cells. American Journal of Physiology - Renal Physiology, 2010, 299, G677-G686.	1.6	10
48	Identification of Y-Box Binding Protein 1 As a Core Regulator of MEK/ERK Pathway-Dependent Gene Signatures in Colorectal Cancer Cells. PLoS Genetics, 2010, 6, e1001231.	1.5	80
49	Molecular Testing in Colorectal Carcinoma. Surgical Pathology Clinics, 2010, 3, 429-445.	0.7	1
50	The Use of COLD-PCR and High-Resolution Melting Analysis Improves the Limit of Detection of KRAS and BRAF Mutations in Colorectal Cancer. Journal of Molecular Diagnostics, 2010, 12, 705-711.	1.2	55
51	The Genetics of Colorectal Cancer. Cancer Metastasis - Biology and Treatment, 2010, , 65-100.	0.1	0
52	Predictive and Prognostic Biomarkers for Targeted Therapy in Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2010, 9, 274-281.	1.0	63
53	Intestinal Stem Cell Aging. Else-Kröner-Fresenius-Symposia, 2010, , 63-78.	0.1	1
54	Epigenomic diversity of colorectal cancer indicated by LINE-1 methylation in a database of 869 tumors. Molecular Cancer, 2010, 9, 125.	7.9	131
55	The tumor microenvironment of colorectal cancer: stromal TLR-4 expression as a potential prognostic marker. Journal of Translational Medicine, 2010, 8, 112.	1.8	120
56	The 2010 American Society of Clinical Oncology Gastrointestinal Cancers Symposium. Clinical Colorectal Cancer, 2010, 9, 77-82.	1.0	0
57	Integrating Biomarkers Into Clinical Decision Making for Colorectal Cancer. Clinical Colorectal Cancer, 2010, 9, S16-S27.	1.0	7
58	Role of the Serrated Pathway in Colorectal Cancer Pathogenesis. Gastroenterology, 2010, 138, 2088-2100.	0.6	844

#	ARTICLE	IF	CITATIONS
59	Design and Synthesis of Novel Diaminoquinazolines with <i>in Vivo</i> Efficacy for Î²-Catenin/T-Cell Transcriptional Factor 4 Pathway Inhibition. Journal of Medicinal Chemistry, 2010, 53, 897-910.	2.9	29
60	The molecular therapy of colorectal cancer. Molecular Aspects of Medicine, 2010, 31, 171-178.	2.7	52
61	Microsatellite instability as a marker of prognosis and response to therapy: A meta-analysis of colorectal cancer survival data. European Journal of Cancer, 2010, 46, 2788-2798.	1.3	328
62	The molecular pathology of cancer. Nature Reviews Clinical Oncology, 2010, 7, 251-265.	12.5	224
63	What can the molecular pathologist offer for optimal decision making?. Annals of Oncology, 2010, 21, vii123-vii129.	0.6	6
64	Consumption of Lycopene Inhibits the Growth and Progression of Colon Cancer in a Mouse Xenograft Model. Journal of Agricultural and Food Chemistry, 2011, 59, 9011-9021.	2.4	59
65	Value of Mismatch Repair, <i>KRAS</i>, and <i>BRAF</i> Mutations in Predicting Recurrence and Benefits From Chemotherapy in Colorectal Cancer. Journal of Clinical Oncology, 2011, 29, 1261-1270.	0.8	593
66	A Molecularly Annotated Platform of Patient-Derived Xenografts (â€œXenopatientsâ€) Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer. Cancer Discovery, 2011, 1, 508-523.	7.7	818
67	Effects of cyclin-dependent kinase 8 specific siRNA on the proliferation and apoptosis of colon cancer cells. Journal of Experimental and Clinical Cancer Research, 2011, 30, 109.	3.5	28
69	The molecular biology of colorectal carcinoma and its implications: A review. Journal of the Royal College of Surgeons of Edinburgh, 2011, 9, 200-210.	0.8	59
71	Distinct Profiles of Epigenetic Evolution between Colorectal Cancers with and without Metastasis. American Journal of Pathology, 2011, 178, 1835-1846.	1.9	38
72	Prognostic and Predictive Markers in Stage II Colon Cancer: Is There a Role for Gene Expression Profiling?. Clinical Colorectal Cancer, 2011, 10, 73-80.	1.0	72
73	Biomarker-based selection of therapy for colorectal cancer. Biomarkers in Medicine, 2011, 5, 319-332.	0.6	12
74	Proteins and an Inflammatory Network Expressed in Colon Tumors. Journal of Proteome Research, 2011, 10, 2129-2139.	1.8	15
75	EGFR/Ras/MAPK Signaling Mediates Adult Midgut Epithelial Homeostasis and Regeneration in Drosophila. Cell Stem Cell, 2011, 8, 84-95.	5.2	406
76	Colorectal tumors: The histology report. Digestive and Liver Disease, 2011, 43, S344-S355.	0.4	30
77	Recent Advances in Biotherapeutics Drug Discovery and Development. , 2011, , .		5
78	Pharmacogenomics of drug metabolizing enzymes and transporters: implications for cancer therapy. Pharmacogenomics and Personalized Medicine, 2011, 4, 11.	0.4	40

#	Article	IF	Citations
79	HDAC Inhibition Decreases the Expression of EGFR in Colorectal Cancer Cells. PLoS ONE, 2011, 6, e18087.	1.1	84
80	The Proteomics of Colorectal Cancer: Identification of a Protein Signature Associated with Prognosis. PLoS ONE, 2011, 6, e27718.	1.1	78
81	Molecular analysis of Fanconi anemia and mismatch repair genes in patients with colorectal carcinoma. Oncology Reports, 2011, 25, 899-904.	1.2	1
83	Personalized Medicine and Oncology Practice Guidelines: A Case Study of Contemporary Biomarkers in Colorectal Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2011, 9, 13-25.	2.3	31
84	DNA Copy Number Profiles Correlate with Outcome in Colorectal Cancer Patients Treated with Fluoropyrimidine/Antifolate-based Regimens. Current Drug Metabolism, 2011, 12, 956-965.	0.7	7
85	CCL3 (MIP-1α) plasma levels and the risk for disease progression in chronic lymphocytic leukemia. Blood, 2011, 117, 1662-1669.	0.6	112
86	RNA expression of the molecular signature genes for metastasis in colorectal cancer. Oncology Reports, 2011, 25, 1321-7.	1.2	4
87	Oncologic Drugs. , 0, , 97-114.		0
89	Roles of cyclin-dependent kinase 8 and β-catenin in the oncogenesis and progression of gastric adenocarcinoma. International Journal of Oncology, 2011, 38, 1375-83.	1.4	36
91	TRAIL-transduced multipotent mesenchymal stromal cells (TRAIL-MSC) overcome TRAIL resistance in selected CRC cell lines in vitro and in vivo. Cancer Gene Therapy, 2011, 18, 229-239.	2.2	85
92	Folate receptor-α expression in resectable hepatic colorectal cancer metastases: patterns and significance. Modern Pathology, 2011, 24, 1221-1228.	2.9	48
93	Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut, 2011, 60, 397-411.	6.1	453
94	Cancer immunology—analysis of host and tumor factors for personalized medicine. Nature Reviews Clinical Oncology, 2011, 8, 711-719.	12.5	251
95	p53 Status and Its Prognostic Role in Extrahepatic Bile Duct Cancer: A Meta-Analysis of Published Studies. Digestive Diseases and Sciences, 2011, 56, 655-662.	1.1	16
96	Molecular profiles and clinical outcome of stage UICC II colon cancer patients. International Journal of Colorectal Disease, 2011, 26, 847-858.	1.0	38
97	Mutations in BRAF correlate with poor survival of colorectal cancers in Chinese population. International Journal of Colorectal Disease, 2011, 26, 1387-1395.	1.0	41
98	Elevated expression of MGb2-Ag/TRAK1 is correlated with poor prognosis in patients with colorectal cancer. International Journal of Colorectal Disease, 2011, 26, 1397-1404.	1.0	9
100	Clinical significance of microsatellite instability for stage II or III colorectal cancer following adjuvant therapy with doxifluridine. Medical Oncology, 2011, 28, 214-218.	1.2	8

#	ARTICLE	IF	CITATIONS
101	The mitochondrial DNA 4,977-bp deletion and its implication in copy number alteration in colorectal cancer. BMC Medical Genetics, 2011, 12, 8.	2.1	103
102	Î²â€Catenin and NFâ€ÎºB cooperate to regulate the uPA/uPAR system in cancer cells. International Journal of Cancer, 2011, 128, 1280-1292.	2.3	50
103	Identification of potential pharmacogenomic markers of clinical efficacy of 5â€fluorouracil in colorectal cancer. International Journal of Cancer, 2011, 128, 1935-1945.	2.3	19
104	Frequent genomic loss at chr16p13.2 is associated with poor prognosis in colorectal cancer. International Journal of Cancer, 2011, 129, 1848-1858.	2.3	41
105	Colorectal cancer molecular biology moves into clinical practice. Gut, 2011, 60, 116-129.	6.1	280
106	Pharmacogenetic interaction analysis for the efficacy of systemic treatment in metastatic colorectal cancer. Annals of Oncology, 2011, 22, 1147-1153.	0.6	39
107	Clinical Validation of Colorectal Cancer Biomarkers Identified from Bioinformatics Analysis of Public Expression Data. Clinical Cancer Research, 2011, 17, 700-709.	3.2	80
108	VEGFA gene locus (6p12) amplification identifies a small but highly aggressive subgroup of colorectal patients. Modern Pathology, 2011, 24, 1404-1412.	2.9	20
109	Association of <i>CHFR</i> Promoter Methylation with Disease Recurrence in Locally Advanced Colon Cancer. Clinical Cancer Research, 2011, 17, 4531-4540.	3.2	32
110	On the Occurrence of the Diabetes-Associated Antigen GAD 65 in Human Sera. International Archives of Allergy and Immunology, 2011, 155, 167-179.	0.9	2
111	Colorectal cancer: are genetic and molecular biology researches reflected enough in the patient management?. Turkish Journal of Surgery, 2011, 27, 198.	1.0	0
112	Rare MDM4 gene amplification in colorectal cancer: The principle of a mutually exclusive relationship between MDM alteration and TP53 inactivation is not applicable. Oncology Reports, 2011, 26, 49-54.	1.2	10
113	Application of the U.S. EPA Mode of Action Framework for Purposes of Guiding Future Research: A Case Study Involving the Oral Carcinogenicity of Hexavalent Chromium. Toxicological Sciences, 2011, 119, 20-40.	1.4	63
114	Trastuzumab and Pertuzumab Produce Changes in Morphology and Estrogen Receptor Signaling in Ovarian Cancer Xenografts Revealing New Treatment Strategies. Clinical Cancer Research, 2011, 17, 4451-4461.	3.2	56
115	The role of Cathepsin S as a marker of prognosis and predictor of chemotherapy benefit in adjuvant CRC: a pilot study. British Journal of Cancer, 2011, 105, 1487-1494.	2.9	62
116	Genetic and Epigenetic Traits as Biomarkers in Colorectal Cancer. International Journal of Molecular Sciences, 2011, 12, 9426-9439.	1.8	42
117	Better value cancer care for the 21st century. Annals of Oncology, 2011, 22, 2541-2545.	0.6	1
118	Hierarchical clustering analysis of pathologic and molecular data identifies prognostically and biologically distinct groups of colorectal carcinomas. Modern Pathology, 2011, 24, 126-137.	2.9	22

#	ARTICLE	IF	CITATIONS
119	Race and Subset Analyses in Clinical Trials: Time to Get Serious About Data Integration. Journal of the National Cancer Institute, 2011, 103, 1486-1488.	3.0	3
120	A curated database of genetic markers from the angiogenesis/VEGF pathway and their relation to clinical outcome in human cancers. Acta OncolÃ³gica, 2012, 51, 243-246.	0.8	7
121	Predictive biomarkers with potential of converting conventional chemotherapy to targeted therapy in patients with metastatic colorectal cancer. Scandinavian Journal of Gastroenterology, 2012, 47, 340-355.	0.6	24
122	Evaluation of predictive markers for patients with advanced colorectal cancer. Acta OncolÃ³gica, 2012, 51, 849-859.	0.8	37
123	Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling. EMBO Journal, 2012, 31, 2629-2647.	3.5	110
124	Alternative Cleavage and Polyadenylation during Colorectal Cancer Development. Clinical Cancer Research, 2012, 18, 5256-5266.	3.2	108
125	Inhibition of MEK and PI3K/mTOR Suppresses Tumor Growth but Does Not Cause Tumor Regression in Patient-Derived Xenografts of RAS-Mutant Colorectal Carcinomas. Clinical Cancer Research, 2012, 18, 2515-2525.	3.2	172
126	The Oncolytic Poxvirus JX-594 Selectively Replicates in and Destroys Cancer Cells Driven by Genetic Pathways Commonly Activated in Cancers. Molecular Therapy, 2012, 20, 749-758.	3.7	231
127	Advances in Cancer Stem Cell Biology. , 2012, , .		3
128	Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Research, 2012, 22, 271-282.	2.4	527
129	Src tyrosine kinase phosphorylation of nuclear receptor HNF4Î± correlates with isoform-specific loss of HNF4Î± in human colon cancer. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 2302-2307.	3.3	76
130	Implementation of a Performance Improvement Initiative in Colorectal Cancer Care. Journal of Oncology Practice, 2012, 8, 309-314.	2.5	12
131	Markers for Screening Lynch Syndrome Are Reliable and Useful for Identifying the Specimen Mislabeling. Korean Journal of Pathology, 2012, 46, 131.	1.2	1
132	Integrative Marker Analysis Allows Risk Assessment for Metastasis in Stage II Colon Cancer. Annals of Surgery, 2012, 256, 763-771.	2.1	67
133	Resectable liver metastases from colorectal cancer: where we are now and where do we go from here?. Colorectal Cancer, 2012, 1, 397-411.	0.8	0
134	Promoter CpG island methylation markers in colorectal cancer: the road ahead. Epigenomics, 2012, 4, 179-194.	1.0	38
135	Dependency of Colorectal Cancer on a TGF-Î²-Driven Program in Stromal Cells for Metastasis Initiation. Cancer Cell, 2012, 22, 571-584.	7.7	881
136	Functional, Genetic, and Epigenetic Aspects of Base and Nucleotide Excision Repair in Colorectal Carcinomas. Clinical Cancer Research, 2012, 18, 5878-5887.	3.2	66

#	Article	IF	Citations
137	Direct and immune mediated antibody targeting of <i>ERBB</i> receptors in a colorectal cancer cell-line panel. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 21046-21051.	3.3	41
138	EGFR and PKC are involved in the activation of ERK1/2 and p90 RSK and the subsequent proliferation of SNU-407 colon cancer cells by muscarinic acetylcholine receptors. Molecular and Cellular Biochemistry, 2012, 370, 191-198.	1.4	25
139	Proteomic-based identification of the APC-binding protein EB1 as a candidate of novel tissue biomarker and therapeutic target for colorectal cancer. Journal of Proteomics, 2012, 75, 5342-5355.	1.2	28
140	Activated leukocyte cell adhesion molecule (CD166)â€"Its prognostic power for colorectal cancer patients. Journal of Surgical Research, 2012, 177, e15-e20.	0.8	54
141	CYP1B1 Asn453Ser polymorphism and colorectal cancer risk: a meta-analysis. Metabolism: Clinical and Experimental, 2012, 61, 1321-1329.	1.5	6
142	Negative Cross-talk between Calcium-sensing Receptor and Î²-Catenin Signaling Systems in Colonic Epithelium. Journal of Biological Chemistry, 2012, 287, 1158-1167.	1.6	63
143	Prognostic gene expression signature associated with two molecularly distinct subtypes of colorectal cancer. Gut, 2012, 61, 1291-1298.	6.1	74
144	Î²-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer. Nature Medicine, 2012, 18, 892-901.	15.2	336
145	Response prediction in metastasised colorectal cancer using intratumoural thymidylate synthase: Results of a randomised multicentre trial. European Journal of Cancer, 2012, 48, 1443-1451.	1.3	13
146	Concomitant consumption of lycopene and fish oil inhibits tumor growth and progression in a mouse xenograft model of colon cancer. Molecular Nutrition and Food Research, 2012, 56, 1520-1531.	1.5	28
147	Polymorphisms in the mitochondrial oxidative phosphorylation chain genes as prognostic markers for colorectal cancer. BMC Medical Genetics, 2012, 13, 31.	2.1	18
148	Study protocol of the SACURA trial: a randomized phase III trial of efficacy and safety of UFT as adjuvant chemotherapy for stage II colon cancer. BMC Cancer, 2012, 12, 281.	1.1	10
149	Triplex DNA-binding proteins are associated with clinical outcomes revealed by proteomic measurements in patients with colorectal cancer. Molecular Cancer, 2012, 11, 38.	7.9	25
150	S100P, a potential novel prognostic marker in colorectal cancer. Oncology Reports, 2012, 28, 303-10.	1.2	32
151	An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients. Annals of Oncology, 2012, 23, 1207-1213.	0.6	40
152	Molecular biomarkers of colorectal cancer: prognostic and predictive tools for clinical practice. Journal of Zhejiang University: Science B, 2012, 13, 663-675.	1.3	19
153	The promise of mTOR inhibitors in the treatment of colorectal cancer. Expert Opinion on Investigational Drugs, 2012, 21, 1775-1788.	1.9	26
154	A Role for the Epidermal Growth Factor Receptor Signaling in Development of Intestinal Serrated Polyps in Mice and Humans. Gastroenterology, 2012, 143, 730-740.	0.6	32

#	ARTICLE	IF	CITATIONS
156	Colorectal cancer chemoprevention by trans-resveratrol. Pharmacological Research, 2012, 65, 584-591.	3.1	97
157	Toponome imaging system: multiplex biomarkers in oncology. Trends in Molecular Medicine, 2012, 18, 723-731.	3.5	9
158	The biology of personalized cancer medicine: Facing individual complexities underlying hallmark capabilities. Molecular Oncology, 2012, 6, 111-127.	2.1	135
159	Paying for personalized care: Cancer biomarkers and comparative effectiveness. Molecular Oncology, 2012, 6, 260-266.	2.1	19
160	<i>TMEM158</i> and <i>FBLP1</i> as novel marker genes of cisplatin sensitivity in non-small cell lung cancer cells. Experimental Lung Research, 2012, 38, 463-474.	0.5	19
161	Genetic Variations in Stem Cell-Related Genes and Colorectal Cancer Prognosis. Journal of Gastrointestinal Cancer, 2012, 43, 584-593.	0.6	5
162	Expression of MSP58 in human colorectal cancer and its correlation with prognosis. Medical Oncology, 2012, 29, 3136-3142.	1.2	11
163	Integrated Analysis of Molecular and Clinical Prognostic Factors in Stage II/III Colon Cancer. Journal of the National Cancer Institute, 2012, 104, 1635-1646.	3.0	227
164	Identification of Pathway Deregulation â€“ Gene Expression Based Analysis of Consistent Signal Transduction. PLoS ONE, 2012, 7, e41541.	1.1	18
165	IgG Expression in Human Colorectal Cancer and Its Relationship to Cancer Cell Behaviors. PLoS ONE, 2012, 7, e47362.	1.1	48
166	Systems Biology Approach to Identify Gene Network Signatures for Colorectal Cancer. Frontiers in Genetics, 2012, 3, 80.	1.1	16
167	Distinct Pathologic Roles for Glycogen Synthase Kinase 3Î² in Colorectal Cancer Progression. , 2012, , .		2
168	Assessing the clinical significance of tumor markers in common neoplasms. Frontiers in Bioscience - Elite, 2012, E4, 2558-2578.	0.9	8
169	Detecting KRAS mutations in peripheral blood of colorectal cancer patients by peptide nucleic acid clamp PCR. Experimental and Therapeutic Medicine, 2012, 4, 790-794.	0.8	11
170	Mutation pattern of KRAS and BRAF oncogenes in colorectal cancer patients. Neoplasma, 2012, 59, 376-383.	0.7	20
171	Prognostic Value of Putative Circulating Cancer Stem Cells in Patients Undergoing Hepatic Resection for Colorectal Liver Metastasis. Annals of Surgical Oncology, 2012, 19, 402-408.	0.7	76
172	Design, Synthesis, and Biological Evaluation of New Diaminoquinazolines as Î²-Catenin/Tcf4 Pathway Inhibitors. Journal of Medicinal Chemistry, 2012, 55, 1346-1359.	2.9	15
173	Detection of polymorphism in the methlyenetetrahydrofolate reductase gene by Raman spectroscopy. Journal of Raman Spectroscopy, 2012, 43, 1083-1088.	1.2	2

#	ARTICLE	IF	CITATIONS
175	Meta-analysis of Histopathological Features of Primary Colorectal Cancers that Predict Lymph Node Metastases. Journal of Gastrointestinal Surgery, 2012, 16, 1019-1028.	0.9	85
176	The molecular basis of chemoradiosensitivity in rectal cancer:implications for personalized therapies. Langenbeck's Archives of Surgery, 2012, 397, 543-555.	0.8	41
177	Immunostaining for mismatch repair (MMR) protein expression in colorectal cancer is better and easier to interpret when performed on diagnostic biopsies. Histopathology, 2012, 60, 653-655.	1.6	18
178	Role of CSN5/JAB1 in Wnt/Î²â€€atenin activation in colorectal cancer cells. FEBS Letters, 2012, 586, 1645-1651.	1.3	30
179	Synthesis, cytotoxicity and structure-activity relationships between ester and amide functionalities in novel acridine-based platinum(II) complexes. Journal of Inorganic Biochemistry, 2012, 110, 51-57.	1.5	6
180	Detection of collagen triple helix repeat containing-1 and nuclear factor (erythroid-derived 2)-like 3 in colorectal cancer. BMC Clinical Pathology, 2012, 12, 2.	1.8	12
181	Identification of secretory gelsolin as a plasma biomarker associated with distant organ metastasis of colorectal cancer. Journal of Molecular Medicine, 2012, 90, 187-200.	1.7	31
183	Association between CYP1A1 polymorphism and colorectal cancer risk: a meta-analysis. Molecular Biology Reports, 2012, 39, 3533-3540.	1.0	30
184	Next generation sequencing and a new era of medicine. Gut, 2013, 62, 920-932.	6.1	24
185	Matrix metalloproteinase 9 expression and prognosis in colorectal cancer: a meta-analysis. Tumor Biology, 2013, 34, 735-741.	0.8	29
186	Preoperative Platelet Count Associates with Survival and Distant Metastasis in Surgically Resected Colorectal Cancer Patients. Journal of Gastrointestinal Cancer, 2013, 44, 293-304.	0.6	49
187	Development of microbiochip for detection of metalloproteinase 7 using fluorescence resonance energy transfer. Biochip Journal, 2013, 7, 164-172.	2.5	7
188	Association study identifying polymorphisms in CD47 and other extracellular matrix pathway genes as putative prognostic markers for colorectal cancer. International Journal of Colorectal Disease, 2013, 28, 173-181.	1.0	21
189	The prognostic significance of <i><scp>APC</scp></i> gene mutation and miRâ€€21 expression in advancedâ€€stage colorectal cancer. Colorectal Disease, 2013, 15, 1367-1374.	0.7	58
190	Laser microdissection and two-dimensional difference gel electrophoresis with alkaline isoelectric point immobiline gel reveals proteomic intra-tumor heterogeneity in colorectal cancer. EuPA Open Proteomics, 2013, 1, 17-29.	2.5	3
191	Laser microdissection and two-dimensional difference gel electrophoresis reveal proteomic intra-tumor heterogeneity in colorectal cancer. Journal of Proteomics, 2013, 78, 134-147.	1.2	16
192	A Study of Cancer Heterogeneity: From Genetic Instability to Epigenetic Diversity in Colorectal Cancer. , 2013, , 363-388.		3
193	Neonatal Fc Receptor Expression in Dendritic Cells Mediates Protective Immunity against Colorectal Cancer. Immunity, 2013, 39, 1095-1107.	6.6	112

#	ARTICLE	IF	CITATIONS
194	A novel classification of colorectal tumors based on microsatellite instability, the CpG island methylator phenotype and chromosomal instability: implications for prognosis. Annals of Oncology, 2013, 24, 2048-2056.	0.6	79
196	Network quantification of EGFR signaling unveils potential for targeted combination therapy. Molecular Systems Biology, 2013, 9, 673.	3.2	158
197	Perspective: Flicking with flow: Can microfluidics revolutionize the cancer research?. Biomicrofluidics, 2013, 7, 011811.	1.2	16
198	Molecular biomarkers in esophageal, gastric, and colorectal adenocarcinoma. , 2013, 140, 133-147.		27
199	A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen. Pharmacogenomics Journal, 2013, 13, 403-409.	0.9	66
200	Hyperactivation of constitutively dimerized oncogenic EGF receptors by autocrine loops. Oncogene, 2013, 32, 2403-2411.	2.6	15
201	Diagnostic utility of MS-MLPA in DNA methylation profiling of adenocarcinomas and neuroendocrine carcinomas of the colonâ€"rectum. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2013, 462, 47-56.	1.4	43
202	<i>MLH1</i>â€"silenced and nonâ€"silenced subgroups of hypermutated colorectal carcinomas have distinct mutational landscapes. Journal of Pathology, 2013, 229, 99-110.	2.1	67
203	Use of multivariate analysis to suggest a new molecular classification of colorectal cancer. Journal of Pathology, 2013, 229, 441-448.	2.1	80
204	RAD51 overexpression is a negative prognostic marker for colorectal adenocarcinoma. International Journal of Cancer, 2013, 132, 2118-2126.	2.3	95
205	Analysis of colorectal cancers in British Bangladeshi identifies early onset, frequent mucinous histotype and a high prevalence of RBFOX1 deletion. Molecular Cancer, 2013, 12, 1.	7.9	154
206	microRNA-7 is a novel inhibitor of YY1 contributing to colorectal tumorigenesis. Oncogene, 2013, 32, 5078-5088.	2.6	194
207	Establishment of tumorâ€"specific copy number alterations from plasma DNA of patients with cancer. International Journal of Cancer, 2013, 133, 346-356.	2.3	155
208	Targeted therapy in metastatic colorectal cancer â€" An example of personalised medicine in action. Cancer Treatment Reviews, 2013, 39, 592-601.	3.4	104
209	High Ran level is correlated with poor prognosis in patients with colorectal cancer. International Journal of Clinical Oncology, 2013, 18, 856-863.	1.0	18
210	Serine, glycine and one-carbon units: cancer metabolism in full circle. Nature Reviews Cancer, 2013, 13, 572-583.	12.8	1,221
211	KRAS and BRAF Mutations in 203 Esophageal Squamous Cell Carcinomas: Pyrosequencing Technology and Literature Review. Annals of Surgical Oncology, 2013, 20, 485-491.	0.7	32
212	An Alternative Pathway in Colorectal Carcinogenesis Based on the Mismatch Repair System and p53 Expression in Korean Patients with Sporadic Colorectal Cancer. Annals of Surgical Oncology, 2013, 20, 4031-4040.	0.7	16

#	ARTICLE	IF	CITATIONS
213	Assessing colorectal cancer heterogeneity: one step closer to tailored medicine. Journal of Applied Biomedicine, 2013, 11, 115-129.	0.6	2
214	From human genome to cancer genome: The first decade. Genome Research, 2013, 23, 1054-1062.	2.4	132
215	Patupilone in patients with pretreated metastatic/locally recurrent colorectal cancer: results of the Phase II CINATRA trial. Investigational New Drugs, 2013, 31, 1339-1344.	1.2	8
216	Polymorphisms correlated with the clinical outcome of locally advanced or metastatic colorectal cancer patients treated with ALIRI vs. FOLFIRI. Pteridines, 2013, 24, 69-79.	0.5	2
217	The National Health Service Bowel Cancer Screening Program: the early years. Expert Review of Gastroenterology and Hepatology, 2013, 7, 421-437.	1.4	31
219	Anticipating the Clinical Use of Prognostic Gene Expression–Based Tests for Colon Cancer Stage II and III: Is Godot Finally Arriving?. Clinical Cancer Research, 2013, 19, 6669-6677.	3.2	27
220	Targeted Degradation of KRAS by an Engineered Ubiquitin Ligase Suppresses Pancreatic Cancer Cell Growth <i>In Vitro</i> and <i>In Vivo</i>. Molecular Cancer Therapeutics, 2013, 12, 286-294.	1.9	43
221	Evaluation of the prognostic value of pSMAD immunohistochemistry in colorectal cancer. European Journal of Cancer Prevention, 2013, 22, 420-424.	0.6	13
222	Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment. Pharmacogenetics and Genomics, 2013, 23, 549-557.	0.7	49
223	Complex Tumor Genomes Inferred from Single Circulating Tumor Cells by Array-CGH and Next-Generation Sequencing. Cancer Research, 2013, 73, 2965-2975.	0.4	497
224	Biomarkers in precision therapy in colorectal cancer. Gastroenterology Report, 2013, 1, 166-183.	0.6	86
225	Postoperative hyperphosphatemia significantly associates with adverse survival in colorectal cancer patients. Journal of Gastroenterology and Hepatology (Australia), 2013, 28, 1469-1475.	1.4	10
226	Impact of Molecular Alterations and Targeted Therapy in Appendiceal Adenocarcinomas. Oncologist, 2013, 18, 1270-1277.	1.9	41
227	Genetic reconstitution of tumorigenesis in primary intestinal cells. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 11127-11132.	3.3	100
228	Radiotherapy Response in Microsatellite Instability Related Rectal Cancer. Korean Journal of Pathology, 2013, 47, 1.	1.2	31
229	CDK8 regulates E2F1 transcriptional activity through S375 phosphorylation. Oncogene, 2013, 32, 3520-3530.	2.6	54
230	A Personalized Preclinical Model to Evaluate the Metastatic Potential of Patient-Derived Colon Cancer Initiating Cells. Clinical Cancer Research, 2013, 19, 6787-6801.	3.2	80
231	Spinophilin Loss Correlates with Poor Patient Prognosis in Advanced Stages of Colon Carcinoma. Clinical Cancer Research, 2013, 19, 3925-3935.	3.2	16

#	Article	IF	Citations
233	Regulation of YAP through an Akt-dependent process by 3, 3′-diindolylmethane in human colon cancer cells. International Journal of Oncology, 2013, 43, 1992-1998.	1.4	26
234	Identification of MXRA5 as a novel biomarker in colorectal cancer. Oncology Letters, 2013, 5, 544-548.	0.8	41
235	Silencing of pancreatic adenocarcinoma upregulated factor by RNA interference inhibits the malignant phenotypes of human colorectal cancer cells. Oncology Reports, 2013, 30, 213-220.	1.2	11
237	SLCO1B1 and SLC19A1 Gene Variants and Irinotecan-Induced Rapid Response and Survival: A Prospective Multicenter Pharmacogenetics Study of Metastatic Colorectal Cancer. PLoS ONE, 2013, 8, e77223.	1.1	24
238	Prognostic Role of microRNA-21 in Colorectal Cancer: a Meta-Analysis. PLoS ONE, 2013, 8, e80426.	1.1	56
239	Recurrence of Early Stage Colon Cancer Predicted by Expression Pattern of Circulating microRNAs. PLoS ONE, 2014, 9, e84686.	1.1	50
240	Role of Toll-Like Receptor 4 in Colorectal Carcinogenesis: A Meta-Analysis. PLoS ONE, 2014, 9, e93904.	1.1	15
241	Current and future molecular diagnostics in colorectal cancer and colorectal adenoma. World Journal of Gastroenterology, 2014, 20, 3847.	1.4	40
242	KRAS <i>and</i> PIK3CA <i>Mutation Frequencies in Patient-derived Xenograft Models of Pancreatic and Colorectal Cancer Are Reflective of Patient Tumors and Stable Across Passages</i>. American Surgeon, 2014, 80, 873-877.	0.4	27
243	Application of Novel Genotyping Microarray Technologies in Cancer Research. Comprehensive Analytical Chemistry, 2014, , 47-73.	0.7	0
244	Ras-Mediated Deregulation of the Circadian Clock in Cancer. PLoS Genetics, 2014, 10, e1004338.	1.5	140
245	Minimal residual disease in early colorectal carcinoma. Trakia Journal of Sciences, 2014, 12, 309-324.	0.0	1
246	Protocadherin 10 suppresses tumorigenesis and metastasis in colorectal cancer and its genetic loss predicts adverse prognosis. International Journal of Cancer, 2014, 135, 2593-2603.	2.3	33
247	Novel role of Sarco/endoplasmic reticulum calcium ATPase 2 in development of colorectal cancer and its regulation by F36, a curcumin analog. Biomedicine and Pharmacotherapy, 2014, 68, 1141-1148.	2.5	44
248	BRAF V600E Mutation as a Predictive Factor of Anti-EGFR Monoclonal Antibodies Therapeutic Effects in Metastatic Colorectal Cancer: a Meta-analysis. Chinese Medical Sciences Journal, 2014, 29, 197-203.	0.2	15
249	Effects of MTHFR Genetic Polymorphisms on Toxicity and Clinical Response of Irinotecan-Based Chemotherapy in Patients with Colorectal Cancer. Genetic Testing and Molecular Biomarkers, 2014, 18, 313-322.	0.3	7
250	Cyclin-dependent kinase-specific activity predicts the prognosis of stage I and stage II non-small cell lung cancer. BMC Cancer, 2014, 14, 755.	1.1	7
251	Overexpression of microRNA-183 in human colorectal cancer and its clinical significance. European Journal of Gastroenterology and Hepatology, 2014, 26, 229-233.	0.8	51

#	ARTICLE	IF	CITATIONS
252	Prognostic factors in pulmonary metastasectomy: spotlight on molecular and radiological markers. European Journal of Cardio-thoracic Surgery, 2014, 45, 408-416.	0.6	24
253	A programmable method for massively parallel targeted sequencing. Nucleic Acids Research, 2014, 42, e88-e88.	6.5	13
254	Current Approaches for Predicting a Lack of Response to Anti-EGFR Therapy inKRASWild-Type Patients. BioMed Research International, 2014, 2014, 1-8.	0.9	10
255	STAT3: An Anti-Invasive Factor in Colorectal Cancer?. Cancers, 2014, 6, 1394-1407.	1.7	11
256	Prognostic Significance of ÃŽÂ²-Catenin, E-Cadherin, and SOX9 in Colorectal Cancer: Results from a Large Population-Representative Series. Frontiers in Oncology, 2014, 4, 118.	1.3	63
257	Colorectal Carcinomas With CpG Island Methylator Phenotype 1 Frequently Contain Mutations in Chromatin Regulators. Gastroenterology, 2014, 146, 530-538.e5.	0.6	76
258	Role of topoisomerase I and thymidylate synthase expression in sporadic colorectal cancer: Associations with clinicopathological and molecular features. Pathology Research and Practice, 2014, 210, 111-117.	1.0	6
259	Prognostic and Predictive Biomarkers: Tools in Personalized Oncology. Molecular Diagnosis and Therapy, 2014, 18, 273-284.	1.6	132
260	EGFR, BRAF and KRAS Status in Patients Undergoing Pulmonary Metastasectomy from Primary Colorectal Carcinoma: A Prospective Follow-Up Study. Annals of Surgical Oncology, 2014, 21, 946-954.	0.7	53
261	Tissue-based biomarkers predicting outcomes in metastatic colorectal cancer: a review. Clinical and Translational Oncology, 2014, 16, 425-435.	1.2	17
262	Genetic polymorphism of DNA methyltransferase 3B 149 C>T and risk of colorectal cancer: a meta-analysis. Tumor Biology, 2014, 35, 2367-2372.	0.8	4
263	Targeting tumour-supportive cellular machineries in anticancer drug development. Nature Reviews Drug Discovery, 2014, 13, 179-196.	21.5	202
264	KRAS mutations: Analytical considerations. Clinica Chimica Acta, 2014, 431, 211-220.	0.5	26
265	'Toxgnostics': an unmet need in cancer medicine. Nature Reviews Cancer, 2014, 14, 440-445.	12.8	29
266	Molecular Alterations and Biomarkers in Colorectal Cancer. Toxicologic Pathology, 2014, 42, 124-139.	0.9	80
267	<i>Fusobacterium</i> in Colonic Flora and Molecular Features of Colorectal Carcinoma. Cancer Research, 2014, 74, 1311-1318.	0.4	389
268	Phosphorylated p38, a negative prognostic biomarker, complements TNM staging prognostication in colorectal cancer. Tumor Biology, 2014, 35, 10487-10495.	0.8	31
269	Gold nanoprobes for detecting DNA adducts. Chemical Communications, 2014, 50, 15517-15520.	2.2	7

#	ARTICLE	IF	CITATIONS
270	New perspectives on β-catenin control of cell fate and proliferation in colon cancer. Food and Chemical Toxicology, 2014, 74, 14-19.	1.8	17
271	High miR-21 expression from FFPE tissues is associated with poor survival and response to adjuvant chemotherapy in colon cancer. International Journal of Cancer, 2014, 134, 1926-1934.	2.3	79
272	Predictive markers of radiotherapy-induced rectal cancer regression. Journal of Clinical Pathology, 2014, 67, 859-864.	1.0	15
273	A survey of tools for variant analysis of next-generation genome sequencing data. Briefings in Bioinformatics, 2014, 15, 256-278.	3.2	480
274	Environmental Exposures, Tumor Heterogeneity, and Colorectal Cancer Outcomes. Current Colorectal Cancer Reports, 2014, 10, 189-194.	1.0	1
275	Cucurbitacin-E Inhibits Multiple Cancer Cells Proliferation Through Attenuation of Wnt/β-Catenin Signaling. Cancer Biotherapy and Radiopharmaceuticals, 2014, 29, 210-214.	0.7	19
276	Routine use of the Ion Torrent AmpliSeq™ Cancer Hotspot Panel for identification of clinically actionable somatic mutations. Clinical Chemistry and Laboratory Medicine, 2014, 52, 707-14.	1.4	123
277	Loss of SMAD4 Alters BMP Signaling to Promote Colorectal Cancer Cell Metastasis via Activation of Rho and ROCK. Gastroenterology, 2014, 147, 196-208.e13.	0.6	150
278	Loss of EphB6 protein expression in human colorectal cancer correlates with poor prognosis. Journal of Molecular Histology, 2014, 45, 555-563.	1.0	21
279	CpG Island Methylator Phenotype Is Associated With Response to Adjuvant Irinotecan-Based Therapy for Stage III Colon Cancer. Gastroenterology, 2014, 147, 637-645.	0.6	118
280	Proteomics for discovery of candidate colorectal cancer biomarkers. World Journal of Gastroenterology, 2014, 20, 3804.	1.4	62
281	E2A Predicts Prognosis of Colorectal Cancer Patients and Regulates Cancer Cell Growth by Targeting miR-320a. PLoS ONE, 2014, 9, e85201.	1.1	19
282	The incidence of mismatch repair gene defects in colorectal liver metastases. Molecular Medicine Reports, 2014, 10, 1003-1006.	1.1	8
283	Real-time Imaging of Myeloid Cells Dynamics in Apc^{Min/+} Intestinal Tumors by Spinning Disk Confocal Microscopy. Journal of Visualized Experiments, 2014, , 51916.	0.2	1
285	KRAS Mutations and M2PK Upregulation in Stool Samples from Individuals with Positive Fecal Occult Blood Tests Screened for Colorectal Cancer. Tumori, 2014, 100, 122-127.	0.6	2
286	A 12-gene signature to distinguish colon cancer patients with better clinical outcome following treatment with 5-fluorouracil or FOLFIRI. Journal of Pathology: Clinical Research, 2015, 1, 160-172.	1.3	8
287	Mouse models of colorectal cancer as preclinical models. BioEssays, 2015, 37, 909-920.	1.2	59
288	The importance of molecular markers for diagnosis and selection of targeted treatments in patients with cancer. Journal of Internal Medicine, 2015, 278, 545-570.	2.7	46

#	ARTICLE	IF	CITATIONS
289	S100P, a calcium-binding protein, is preferentially associated with the growth of polypoid tumors in colorectal cancer. International Journal of Molecular Medicine, 2015, 35, 675-683.	1.8	8
290	MicroRNA-219-5p functions as aÂtumor suppressor partially by targeting platelet-derived growth factor receptor alpha in colorectal cancer. Neoplasma, 2015, 62, 855-863.	0.7	14
291	Genome Wide Association Study for Predictors of Progression Free Survival in Patients on Capecitabine, Oxaliplatin, Bevacizumab and Cetuximab in First-Line Therapy of Metastatic Colorectal Cancer. PLoS ONE, 2015, 10, e0131091.	1.1	13
292	Nemo-like kinase expression predicts poor survival in colorectal cancer. Molecular Medicine Reports, 2015, 11, 1181-1187.	1.1	7
293	PIK3CA Amplification Is Common in Left Side-Tubular Adenomas but Uncommon Sessile Serrated Adenomas Exclusively with KRAS Mutation. International Journal of Medical Sciences, 2015, 12, 349-353.	1.1	3
294	Genomic medicine and targeted therapy for solid tumors. Journal of Surgical Oncology, 2015, 111, 38-42.	0.8	13
295	Methylation status at HYAL2 predicts overall and progression-free survival of colon cancer patients under 5-FU chemotherapy. Genomics, 2015, 106, 348-354.	1.3	17
296	Colorectal Cancer Heterogeneity and Targeted Therapy: A Case for Molecular Disease Subtypes. Cancer Research, 2015, 75, 245-249.	0.4	163
297	Stromal contribution to the colorectal cancer transcriptome. Nature Genetics, 2015, 47, 312-319.	9.4	520
298	Establishment and characterization of models of chemotherapy resistance in colorectal cancer: Towards a predictive signature of chemoresistance. Molecular Oncology, 2015, 9, 1169-1185.	2.1	91
299	Microsatellite instability and mutations in BRAF and KRAS are significant predictors of disseminated disease in colon cancer. BMC Cancer, 2015, 15, 125.	1.1	35
300	Molecular Characteristics of Basaloid Squamous Cell Carcinoma of the Esophagus: Analysis of KRAS, BRAF, and PIK3CA Mutations and LINE-1 Methylation. Annals of Surgical Oncology, 2015, 22, 3659-3665.	0.7	20
301	DNA Hypermethylation of SHISA3 in Colorectal Cancer: An Independent Predictor of Poor Prognosis. Annals of Surgical Oncology, 2015, 22, 1481-1489.	0.7	20
302	Analyses of 7,635 Patients with Colorectal Cancer Using Independent Training and Validation Cohorts Show That rs9929218 in *CDH1* Is a Prognostic Marker of Survival. Clinical Cancer Research, 2015, 21, 3453-3461.	3.2	24
303	MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by *TP53* Mutation in Preclinical Models of Colorectal Cancer. Clinical Cancer Research, 2015, 21, 5499-5510.	3.2	18
304	Cancer 2015: a longitudinal whole-of-system study of genomic cancer medicine. Drug Discovery Today, 2015, 20, 1429-1432.	3.2	1
305	Mitochondrial DNA copy number in colorectal cancer: between tissue comparisons, clinicopathological characteristics and survival. Carcinogenesis, 2015, 36, bgv151.	1.3	36
306	Directly targeting transcriptional dysregulation in cancer. Nature Reviews Cancer, 2015, 15, 686-694.	12.8	95

#	Article	IF	Citations
307	ERK2-Dependent Phosphorylation of CSN6 Is Critical in Colorectal Cancer Development. Cancer Cell, 2015, 28, 183-197.	7.7	67
308	Integrated transcriptional profiling and genomic analyses reveal RPN2 and HMGB1 as promising biomarkers in colorectal cancer. Cell and Bioscience, 2015, 5, 53.	2.1	29
309	Molecular biology of colorectal cancer in clinical practice. Molecular Biology, 2015, 49, 471-479.	0.4	1
310	Clinical relevance of the differential expression of the glycosyltransferase gene GCNT3 in colon cancer. European Journal of Cancer, 2015, 51, 1-8.	1.3	28
311	The Molecular Pathogenesis of Colorectal Cancer and Its Potential Application to Colorectal Cancer Screening. Digestive Diseases and Sciences, 2015, 60, 762-772.	1.1	136
312	IgG1 antiâ€epidermal growth factor receptor antibodies induce CD8â€dependent antitumor activity. International Journal of Cancer, 2015, 136, 821-830.	2.3	22
313	Diet supplementation with cholic acid promotes intestinal epithelial proliferation in rats exposed to Î³-radiation. Toxicology Letters, 2015, 232, 246-252.	0.4	6
314	Predictive and Prognostic Markers in the Treatment of Metastatic Colorectal Cancer (mCRC). Hematology/Oncology Clinics of North America, 2015, 29, 43-60.	0.9	24
315	Adjuvant Systemic Therapy in Stage II and III Colon Cancer. , 2016, , .		0
317	Proteomics: An Indispensable Tool for Novel Biomarker Identification in Melanoma. Journal of Data Mining in Genomics & Proteomics, 2016, 7, .	0.5	2
318	Prognostic Epigenetics. , 2016, , 177-195.		0
319	Microsatellite Instability in Colorectal Cancer. , 2016, , .		1
320	BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis. PLoS ONE, 2016, 11, e0151865.	1.1	43
321	Phenotype transformation of immortalized NCM460 colon epithelial cell line by TGF-Î²1 is associated with chromosome instability. Molecular Biology Reports, 2016, 43, 1069-1078.	1.0	8
322	Highly sensitive detection of the PIK3CA H1047R mutation in colorectal cancer using a novel PCR-RFLP method. BMC Cancer, 2016, 16, 454.	1.1	10
323	Evaluation of anti-tumorigenic activity of BP3B against colon cancer with patient-derived tumor xenograft model. BMC Complementary and Alternative Medicine, 2016, 16, 473.	3.7	10
324	Circulating microRNA profile predicts disease progression in patients receiving second-line treatment of lapatinib and capecitabine for metastatic pancreatic cancer. Oncology Letters, 2016, 11, 1645-1650.	0.8	20
325	Circulating Tumor Cells Versus Circulating Tumor DNA in Colorectal Cancer: Pros and Cons. Current Colorectal Cancer Reports, 2016, 12, 151-161.	1.0	55

#	ARTICLE	IF	CITATIONS
326	Ordering cancer mutational profiles of cross-sectional copy number alterations. International Journal of Data Mining and Bioinformatics, 2016, 15, 59.	0.1	1
327	Epigenetics, Energy Balance, and Cancer. Energy Balance and Cancer, 2016, , .	0.2	2
328	Epigenetics, Obesity, and Colon Cancer. Energy Balance and Cancer, 2016, , 211-233.	0.2	0
329	Activation of Epidermal Growth Factor Receptor in Macrophages Mediates Feedback Inhibition of M2 Polarization and Gastrointestinal Tumor Cell Growth. Journal of Biological Chemistry, 2016, 291, 20462-20472.	1.6	26
330	Lycopene Consumption and Risk of Colorectal Cancer: A Meta-Analysis of Observational Studies. Nutrition and Cancer, 2016, 68, 1083-1096.	0.9	21
331	Prospective Dutch colorectal cancer cohort: an infrastructure for long-term observational, prognostic, predictive and (randomized) intervention research. Acta Oncológica, 2016, 55, 1273-1280.	0.8	62
332	Dysregulated Wnt signalling and recurrent mutations of the tumour suppressor <i><scp>RNF43</scp></i> in early gastric carcinogenesis. Journal of Pathology, 2016, 240, 304-314.	2.1	44
333	Advances in Biomarkers: Going Beyond the Carcinoembryonic Antigen. Clinics in Colon and Rectal Surgery, 2016, 29, 196-204.	0.5	10
336	Correlation between Gene Variants, Signaling Pathways, and Efficacy of Chemotherapy Drugs against Colon Cancers. Cancer Informatics, 2016, 15, CIN.S34506.	0.9	13
338	Integrated genomic analysis of colorectal cancer progression reveals activation of EGFR through demethylation of the EREG promoter. Oncogene, 2016, 35, 6403-6415.	2.6	58
339	Epidermal Growth Factor Receptor Signaling to the Mitogen Activated Protein Kinase Pathway Bypasses Ras in Pancreatic Cancer Cells. Pancreas, 2016, 45, 286-292.	0.5	12
340	Tumor-Infiltrating Lymphocytes, Crohn's-Like Lymphoid Reaction, and Survival From Colorectal Cancer. Journal of the National Cancer Institute, 2016, 108, .	3.0	162
341	Clinical Validation and Implementation of a Targeted Next-Generation Sequencing Assay to Detect Somatic Variants in Non-Small Cell Lung, Melanoma, and Gastrointestinal Malignancies. Journal of Molecular Diagnostics, 2016, 18, 299-315.	1.2	55
342	Identifying molecular subtypes in human colon cancer using gene expression and DNA methylation microarray data. International Journal of Oncology, 2016, 48, 690-702.	1.4	21
343	Personalised cancer care: promises and challenges of targeted therapy. Journal of the Royal Society of Medicine, 2016, 109, 98-105.	1.1	13
344	A randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-type <i>KRAS</i> who have received first-line systemic therapy. International Journal of Cancer, 2016, 139, 177-186.	2.3	52
345	Micro<scp>RNA</scp>-27b suppresses tumor progression by regulating <scp>ARFGEF</scp>1 and focal adhesion signaling. Cancer Science, 2016, 107, 28-35.	1.7	39
346	Wildtype adult stem cells, unlike tumor cells, are resistant to cellular damages in Drosophila. Developmental Biology, 2016, 411, 207-216.	0.9	23

#	ARTICLE	IF	CITATIONS
347	Elevated Coexpression of KITENIN and the ErbB4 CYT-2 Isoform Promotes the Transition from Colon Adenoma to Carcinoma Following <i>APC</i> loss. Clinical Cancer Research, 2016, 22, 1284-1294.	3.2	23
348	Molecular evolution of colorectal cancer: from multistep carcinogenesis to the big bang. Cancer and Metastasis Reviews, 2016, 35, 63-74.	2.7	29
350	Role of epithelial cells in the pathogenesis and treatment of inflammatory bowel disease. Journal of Gastroenterology, 2016, 51, 11-21.	2.3	159
351	The lncRNA CRNDE promotes colorectal cancer cell proliferation and chemoresistance via miR-181a-5p-mediated regulation of Wnt/Î²-catenin signaling. Molecular Cancer, 2017, 16, 9.	7.9	402
352	Bowel cancer screening. Surgery, 2017, 35, 132-139.	0.1	0
353	Screening and Identification of Molecular Marker for Metastatic Liver Cancer. , 2017, , 59-91.		0
354	miR-15a-5p, A Novel Prognostic Biomarker, Predicting Recurrent Colorectal Adenocarcinoma. Molecular Diagnosis and Therapy, 2017, 21, 453-464.	1.6	40
355	The Dickkopf1â€cytoskeletonâ€associated protein 4 axis creates a novel signalling pathway and may represent a molecular target for cancer therapy. British Journal of Pharmacology, 2017, 174, 4651-4665.	2.7	47
356	Impact of MLH1 expression on tumor evolution after curative surgical tumor resection in a murine orthotopic xenograft model for human MSI colon cancer. Genes Chromosomes and Cancer, 2017, 56, 681-690.	1.5	2
357	Downregulation of serum metabolite GTA-446 as a novel potential marker for early detection of colorectal cancer. British Journal of Cancer, 2017, 117, 227-232.	2.9	12
358	RSPO2 suppresses colorectal cancer metastasis by counteracting the Wnt5a/Fzd7-driven noncanonical Wnt pathway. Cancer Letters, 2017, 402, 153-165.	3.2	59
359	Upregulation of WEE1 is a potential prognostic biomarker for patients with colorectal cancer. Oncology Letters, 2017, 13, 4341-4348.	0.8	20
360	Predictive model for highâ€frequency microsatellite instability in colorectal cancer patients over 50Âyears of age. Cancer Medicine, 2017, 6, 1255-1263.	1.3	27
361	Overexpression of MutL homolog 1 and MutS homolog 2 proteins have reversed prognostic implications for stage Iâ€"II colon cancer patients. Biomedical Journal, 2017, 40, 39-48.	1.4	15
362	From tumour heterogeneity to advances in precision treatment of colorectal cancer. Nature Reviews Clinical Oncology, 2017, 14, 235-246.	12.5	466
363	LncRNA NEAT1 Impacts Cell Proliferation and Apoptosis of Colorectal Cancer via Regulation of Akt Signaling. Pathology and Oncology Research, 2017, 23, 651-656.	0.9	78
364	Elevated expression of miR-24-3p is a potentially adverse prognostic factor in colorectal adenocarcinoma. Clinical Biochemistry, 2017, 50, 285-292.	0.8	31
365	Upregulated miR-16 expression is an independent indicator of relapse and poor overall survival of colorectal adenocarcinoma patients. Clinical Chemistry and Laboratory Medicine, 2017, 55, 737-747.	1.4	33

#	ARTICLE	IF	CITATIONS
366	Chromosomal instability analysis and regional tumor heterogeneity in colon cancer. Cancer Genetics, 2017, 210, 9-21.	0.2	21
367	High-throughput RNAi screen for essential genes and drug synergistic combinations in colorectal cancer. Scientific Data, 2017, 4, 170139.	2.4	11
368	Phospholipase D1 Inhibition Linked to Upregulation of ICAT Blocks Colorectal Cancer Growth Hyperactivated by Wnt/Î²-Catenin and PI3K/Akt Signaling. Clinical Cancer Research, 2017, 23, 7340-7350.	3.2	41
369	The potential of liquid biopsies for the early detection of cancer. Npj Precision Oncology, 2017, 1, 36.	2.3	126
370	Bax is involved in the anticancer activity of Velcade in colorectal cancer. Experimental and Therapeutic Medicine, 2017, 14, 3179-3183.	0.8	5
371	Cromolyn chitosan nanoparticles as a novel protective approach for colorectal cancer. Chemico-Biological Interactions, 2017, 275, 1-12.	1.7	25
372	FBW7 Loss Promotes Chromosomal Instability and Tumorigenesis via Cyclin E1/CDK2â€"Mediated Phosphorylation of CENP-A. Cancer Research, 2017, 77, 4881-4893.	0.4	68
373	Berberine inhibits colitis-associated tumorigenesis via suppressing inflammatory responses and the consequent EGFR signaling-involved tumor cell growth. Laboratory Investigation, 2017, 97, 1343-1353.	1.7	51
374	Exploitation of Gene Expression and Cancer Biomarkers in Paving the Path to Era of Personalized Medicine. Genomics, Proteomics and Bioinformatics, 2017, 15, 220-235.	3.0	96
375	Simple classifiers for molecular subtypes of colorectal cancer. Arab Journal of Gastroenterology, 2017, 18, 191-200.	0.4	3
376	RBP4-STRA6 Pathway Drives Cancer Stem Cell Maintenance and Mediates High-Fat Diet-Induced Colon Carcinogenesis. Stem Cell Reports, 2017, 9, 438-450.	2.3	78
377	<i>BRAF</i> and <i>NRAS</i> Locus-Specific Variants Have Different Outcomes on Survival to Colorectal Cancer. Clinical Cancer Research, 2017, 23, 2742-2749.	3.2	32
378	FERMT1 mediates epithelialâ€"mesenchymal transition to promote colon cancer metastasis via modulation of Î²-catenin transcriptional activity. Oncogene, 2017, 36, 1779-1792.	2.6	82
379	An enzyme immunoassay for determining epidermal growth factor (EGF) in human serum samples using an ultramicroanalytical system. Journal of Immunoassay and Immunochemistry, 2017, 38, 190-201.	0.5	7
380	Profiles of differentially expressed genes and overexpression of NEBL indicates a positive prognosis in patients with colorectal cancer. Molecular Medicine Reports, 2018, 17, 3028-3034.	1.1	8
381	The Role of Epidermal Growth Factor Receptor in the Management of Gastrointestinal Carcinomas: Present Status and Future Perspectives. Current Pharmaceutical Design, 2017, 23, 2314-2320.	0.9	10
382	Clinical implications of pre-existing adenoma in endoscopically resected early gastric cancers. PLoS ONE, 2017, 12, e0178419.	1.1	4
383	p53/microRNA-374b/AKT1 regulates colorectal cancer cell apoptosis in response to DNA damage. International Journal of Oncology, 2017, 50, 1785-1791.	1.4	31

#	ARTICLE	IF	CITATIONS
384	Downregulation of nuclear and cytoplasmic Chibby is associated with advanced cervical cancer. Oncology Letters, 2017, 14, 6632-6644.	0.8	0
385	Simplified microsatellite instability detection protocol provides equivalent sensitivity to robust detection strategies in Lynch syndrome patients. Cancer Biology and Medicine, 2017, 14, 142.	1.4	5
386	Rapid and accurate detection of <i>KRAS</i> mutations in colorectal cancers using the isothermal-based optical sensor for companion diagnostics. Oncotarget, 2017, 8, 83860-83871.	0.8	15
387	Colorectal Cancer from Molecular Pathways to Gene Therapy. Oncomedicine, 2017, 2, 93-101.	1.1	2
388	Computational Errors and Biases in Short Read Next Generation Sequencing. Journal of Proteomics and Bioinformatics, 2017, 10, .	0.4	26
390	Impairment of Kâ€Ras signaling networks and increased efficacy of epidermal growth factor receptor inhibitors by a novel synthetic miRâ€143. Cancer Science, 2018, 109, 1455-1467.	1.7	36
391	Hereditary gastrointestinal carcinomas and their precursors: An algorithm for genetic testing. Seminars in Diagnostic Pathology, 2018, 35, 170-183.	1.0	20
392	High-fat diet and colorectal cancer: myths and facts. Future Oncology, 2018, 14, 493-495.	1.1	10
393	Clinicopathological, genomic and immunological factors in colorectal cancer prognosis. British Journal of Surgery, 2018, 105, e99-e109.	0.1	39
394	Low penetrance genetic polymorphisms as potential biomarkers for colorectal cancer predisposition. Journal of Gene Medicine, 2018, 20, e3010.	1.4	32
395	<scp>MAD</scp>2L2 inhibits colorectal cancer growth by promoting <scp>NCOA</scp>3 ubiquitination and degradation. Molecular Oncology, 2018, 12, 391-405.	2.1	22
396	Evolving notions on immune response in colorectal cancer and their implications for biomarker development. Inflammation Research, 2018, 67, 375-389.	1.6	32
397	Glycan analysis of colorectal cancer samples reveals stage-dependent changes in CEA glycosylation patterns. Clinical Proteomics, 2018, 15, 9.	1.1	44
398	NF-Î°B pathways in the development and progression of colorectal cancer. Translational Research, 2018, 197, 43-56.	2.2	164
399	<i>MPO</i> Promoter Polymorphism rs2333227 Enhances Malignant Phenotypes of Colorectal Cancer by Altering the Binding Affinity of AP-2Î±. Cancer Research, 2018, 78, 2760-2769.	0.4	15
400	The molecular landscape of synchronous colorectal cancer reveals genetic heterogeneity. Carcinogenesis, 2018, 39, 708-718.	1.3	28
401	Model-Based Phenotypic Signatures Governing the Dynamics of the Stem and Semi-differentiated Cell Populations in Dysplastic Colonic Crypts. Bulletin of Mathematical Biology, 2018, 80, 360-384.	0.9	3
402	MicroRNA-21 induces loss of 15-hydroxyprostaglandin dehydrogenase in early gastric tubular adenocarcinoma. Scientific Reports, 2018, 8, 17717.	1.6	10

#	ARTICLE	IF	CITATIONS
403	Targeting the PI3K Signalling as a Therapeutic Strategy in Colorectal Cancer. Advances in Experimental Medicine and Biology, 2018, 1110, 35-53.	0.8	16
404	Targeted Therapy of Colorectal Cancer Subtypes. Advances in Experimental Medicine and Biology, 2018, , .	0.8	0
405	Tumor p16INK4 gene expression and prognosis in colorectal cancer. Oncology Reports, 2019, 41, 1367-1376.	1.2	4
406	Continuity of transcriptomes among colorectal cancer subtypes based on meta-analysis. Genome Biology, 2018, 19, 142.	3.8	20
407	SP1-induced lncRNA-ZFAS1 contributes to colorectal cancer progression via the miR-150-5p/VEGFA axis. Cell Death and Disease, 2018, 9, 982.	2.7	165
408	SNHG6 Promotes Tumor Growth via Repression of P21 in Colorectal Cancer. Cellular Physiology and Biochemistry, 2018, 49, 463-478.	1.1	38
410	Impact of loss–of–function mutations at the *RNF43* locus on colorectal cancer development and progression. Journal of Pathology, 2018, 245, 445-455.	2.1	39
411	Mutant p53-Expressing Cells Undergo Necroptosis via Cell Competition with the Neighboring Normal Epithelial Cells. Cell Reports, 2018, 23, 3721-3729.	2.9	42
412	The Differential Expression of Core Genes in Nucleotide Excision Repair Pathway Indicates Colorectal Carcinogenesis and Prognosis. BioMed Research International, 2018, 2018, 1-10.	0.9	11
413	Predicting treatment benefit in multiple myeloma through simulation of alternative treatment effects. Nature Communications, 2018, 9, 2943.	5.8	23
414	Shifts of Faecal Microbiota During Sporadic Colorectal Carcinogenesis. Scientific Reports, 2018, 8, 10329.	1.6	99
415	Colorectal Cancer: Genetic Abnormalities, Tumor Progression, Tumor Heterogeneity, Clonal Evolution and Tumor-Initiating Cells. Medical Sciences (Basel, Switzerland), 2018, 6, 31.	1.3	167
416	Mechanistic Insights into Colorectal Cancer Phenomics from Fundamental and Organotypic Model Studies. American Journal of Pathology, 2018, 188, 1936-1948.	1.9	7
417	Sensitivity of Colorectal Cancer to Arginine Deprivation Therapy is Shaped by Differential Expression of Urea Cycle Enzymes. Scientific Reports, 2018, 8, 12096.	1.6	55
418	Molecular subtyping of colorectal cancer: Recent progress, new challenges and emerging opportunities. Seminars in Cancer Biology, 2019, 55, 37-52.	4.3	125
419	Epigenome Mapping Identifies Tumor-Specific Gene Expression in Primary Rectal Cancer. Cancers, 2019, 11, 1142.	1.7	10
420	Diet, Microbiota, and Colorectal Cancer. IScience, 2019, 21, 168-187.	1.9	21
421	Circulating tumor cell free DNA from plasma and urine in the clinical management of colorectal cancer. Cancer Biomarkers, 2019, 27, 29-37.	0.8	27

#	Article	IF	Citations
422	Metformin inhibits β-catenin phosphorylation on Ser-552 through an AMPK/PI3K/Akt pathway in colorectal cancer cells. International Journal of Biochemistry and Cell Biology, 2019, 112, 88-94.	1.2	32
423	Prostaglandin E2 as a potent therapeutic target for treatment of colon cancer. Prostaglandins and Other Lipid Mediators, 2019, 144, 106338.	1.0	79
424	DPS-2: A Novel Dual MEK/ERK and PI3K/AKT Pathway Inhibitor with Powerful Ex Vivo and In Vivo Anticancer Properties. Translational Oncology, 2019, 12, 932-950.	1.7	13
425	Regulation Mechanism of Long Noncoding RNAs in Colon Cancer Development and Progression. Yonsei Medical Journal, 2019, 60, 319.	0.9	46
426	Association of genetic ancestry with colorectal tumor location in Puerto Rican Latinos. Human Genomics, 2019, 13, 12.	1.4	10
427	Inhibition of phosphodiesterase 4D decreases the malignant properties of DLD‑1 colorectal cancer cells by repressing the AKT/mTOR/Myc signaling pathway. Oncology Letters, 2019, 17, 3589-3598.	0.8	16
428	Role of HDAC3-miRNA-CAGE Network in Anti-Cancer Drug-Resistance. International Journal of Molecular Sciences, 2019, 20, 51.	1.8	18
429	Microsatellite instability and sensitivity to fluoropyrimidine and oxaliplatin containing first-line chemotherapy in metastatic colorectal cancer. European Journal of Hospital Pharmacy, 2020, 27, 267-270.	0.5	4
430	High‑risk Stage III colon cancer patients identified by a novel five‑gene mutational signature are characterized by upregulation of IL‑23A and gut bacterial translocation of the tumor microenvironment. International Journal of Cancer, 2020, 146, 2027-2035.	2.3	43
431	Gene expression and methylation profiles identified CXCL3 and CXCL8 as key genes for diagnosis and prognosis of colon adenocarcinoma. Journal of Cellular Physiology, 2020, 235, 4902-4912.	2.0	46
432	Fuzzy Recurrence Plots and Networks with Applications in Biomedicine. , 2020, , .		11
433	Comprehensive analysis of colorectal cancer-risk loci and survival outcome: A prognostic role for CDH1 variants. European Journal of Cancer, 2020, 124, 56-63.	1.3	10
434	Bowel cancer screening. Surgery, 2020, 38, 18-26.	0.1	0
435	Prognostic significance of serum p53 antibody according to KRAS status in metastatic colorectal cancer patients. International Journal of Clinical Oncology, 2020, 25, 651-659.	1.0	4
436	Landscape of Genome-Wide DNA Methylation of Colorectal Cancer Metastasis. Cancers, 2020, 12, 2710.	1.7	18
437	EMAST frequency in colorectal cancer: a meta-analysis and literature review. Biomarkers in Medicine, 2020, 14, 1021-1030.	0.6	3
438	Long Noncoding RNA PCAT18 Upregulates SPRR3 to Promote Colorectal Cancer Progression by Binding to miR-759 . Cancer Management and Research, 2020, Volume 12, 11445-11452.	0.9	7
439	Shared Immunogenic Poly-Epitope Frameshift Mutations in Microsatellite Unstable Tumors. Cell, 2020, 183, 1634-1649.e17.	13.5	103

#	ARTICLE	IF	CITATIONS
440	Circular RNA hsa_circRNA_102209 promotes the growth and metastasis of colorectal cancer through miRâ€761â€mediated Ras and Rab interactor 1 signaling. Cancer Medicine, 2020, 9, 6710-6725.	1.3	32
441	Ribosome Biogenesis Alterations in Colorectal Cancer. Cells, 2020, 9, 2361.	1.8	28
442	A phospho-switch controls RNF43-mediated degradation of Wnt receptors to suppress tumorigenesis. Nature Communications, 2020, 11, 4586.	5.8	40
443	Identification of Tumorigenic and Prognostic Biomarkers in Colorectal Cancer Based on microRNA Expression Profiles. BioMed Research International, 2020, 2020, 1-8.	0.9	5
444	Molecular Pathogenesis and Classification of Colorectal Carcinoma. Current Colorectal Cancer Reports, 2020, 16, 97-106.	1.0	12
445	Prognostic and Predictive Cross-Roads of Microsatellite Instability and Immune Response to Colon Cancer. International Journal of Molecular Sciences, 2020, 21, 9680.	1.8	17
446	Mechanistic Hypotheses on Colorectal Cancer and Red Meat Intake: A Review. IOP Conference Series: Earth and Environmental Science, 2020, 426, 012176.	0.2	3
447	Predictive Potential of PD-L1, TYMS, and DCC Expressions in Treatment Outcome of Colorectal Carcinoma. Advances in Experimental Medicine and Biology, 2020, 1292, 97-112.	0.8	2
448	TRF2 and VEGF-A: an unknown relationship with prognostic impact on survival of colorectal cancer patients. Journal of Experimental and Clinical Cancer Research, 2020, 39, 111.	3.5	14
449	Methylation-Based Therapies for Colorectal Cancer. Cells, 2020, 9, 1540.	1.8	29
450	Effect of Flightless I Expression on Epidermal Stem Cell Niche During Wound Repair. Advances in Wound Care, 2020, 9, 161-173.	2.6	9
451	Multiple gene promoter methylation and clinical stage in adjacent normal tissues: Effect on prognosis of colorectal cancer in Taiwan. Scientific Reports, 2020, 10, 145.	1.6	4
452	Drug Resistance Biomarkers and Their Clinical Applications in Childhood Acute Lymphoblastic Leukemia. Frontiers in Oncology, 2019, 9, 1496.	1.3	20
453	Targeting Histone Chaperone FACT Complex Overcomes 5-Fluorouracil Resistance in Colon Cancer. Molecular Cancer Therapeutics, 2020, 19, 258-269.	1.9	17
454	Image-Based Network Analysis of DNp73 Expression by Immunohistochemistry in Rectal Cancer Patients. Frontiers in Physiology, 2019, 10, 1551.	1.3	4
455	The heterogeneous clinical and pathological landscapes of metastatic Braf-mutated colorectal cancer. Cancer Cell International, 2020, 20, 30.	1.8	63
456	A polymorphism within the R-spondin 2 gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab: data from FIRE-3 and TRIBE trials. European Journal of Cancer, 2020, 131, 89-97.	1.3	9
457	Exosomal KRAS mutation promotes the formation of tumor-associated neutrophil extracellular traps and causes deterioration of colorectal cancer by inducing IL-8 expression. Cell Communication and Signaling, 2020, 18, 52.	2.7	62

#	Article	IF	Citations
458	Applications and strategies in nanodiagnosis and nanotherapy in lung cancer. Seminars in Cancer Biology, 2021, 69, 349-364.	4.3	86
459	Gene dysregulation analysis builds a mechanistic signature for prognosis and therapeutic benefit in colorectal cancer. Journal of Molecular Cell Biology, 2021, 12, 881-893.	1.5	3
460	Prognostic value of <i>BRAF</i>/MIRâ€‘17 signature and Bâ€‘Raf protein expression in patients with colorectal cancer: A pilot study. Journal of Clinical Laboratory Analysis, 2021, 35, e23679.	0.9	11
461	Exome sequencing identifies ARID2 as a novel tumor suppressor in early-onset sporadic rectal cancer. Oncogene, 2021, 40, 863-874.	2.6	25
462	fMRI and transcranial electrical stimulation (tES): A systematic review of parameter space and outcomes. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 107, 110149.	2.5	20
463	Nucleolar protein NOP2 could serve as a potential prognostic predictor for clear cell renal cell carcinoma. Bioengineered, 2021, 12, 4841-4855.	1.4	16
464	Roles of miRNA dysregulation in the pathogenesis of multiple myeloma. Cancer Gene Therapy, 2021, 28, 1256-1268.	2.2	42
465	A Metabolism-Related Radiomics Signature for Predicting the Prognosis of Colorectal Cancer. Frontiers in Molecular Biosciences, 2020, 7, 613918.	1.6	14
466	circ_0000467 promotes the proliferation, metastasis, and angiogenesis in colorectal cancer cells through regulating KLF12 expression by sponging miR-4766-5p. Open Medicine (Poland), 2021, 16, 1415-1427.	0.6	7
467	A Multi-Learning Training Approach for Distinguishing Low and High Risk Cancer Patients. IEEE Access, 2021, 9, 115453-115465.	2.6	3
468	Postâ€‘translational Wnt receptor regulation: Is the fog slowly clearing?. BioEssays, 2021, 43, e2000297.	1.2	10
469	Prognostic Molecular Indices of Resectable Hepatocellular Carcinoma: Implications of S100P for Early Recurrence. Annals of Surgical Oncology, 2021, 28, 6466-6478.	0.7	6
470	Assessment of mismatch repair deficiency, CDX2, beta-catenin and E-cadherin expression in colon cancer: molecular characteristics and impact on prognosis and survival â€“ an immunohistochemical study. Romanian Journal of Morphology and Embryology, 2021, 61, 715-727.	0.4	4
471	Impact of preoperative antibiotics and other variables on integrated microbiome-host transcriptomic data generated from colorectal cancer resections. World Journal of Gastroenterology, 2021, 27, 1465-1482.	1.4	4
472	Whole exome sequencing of a gut-associated lymphoid tissue neoplasm points to precursor or early form of sporadic colon carcinoma. Pathology Research and Practice, 2021, 220, 153406.	1.0	1
473	Integrated approaches for precision oncology in colorectal cancer: The more you know, the better. Seminars in Cancer Biology, 2022, 84, 199-213.	4.3	35
474	CBFÎ² promotes colorectal cancer progression through transcriptionally activating OPN, FAM129A, and UPP1 in a RUNX2-dependent manner. Cell Death and Differentiation, 2021, 28, 3176-3192.	5.0	12
475	Association of Alpha B-Crystallin Expression with Tumor Differentiation Grade in Colorectal Cancer Patients. Diagnostics, 2021, 11, 896.	1.3	4

#	ARTICLE	IF	CITATIONS
476	Acrolein contributes to human colorectal tumorigenesis through the activation of RAS-MAPK pathway. Scientific Reports, 2021, 11, 12590.	1.6	5
477	Analysis of <scp><i>KRAS</i> G12</scp>/<scp>G13</scp> in colorectal cancer using an economical digital <scp>PCR</scp> assay that unequivocally differentiates missense and synonymous alleles. Canadian Journal of Chemical Engineering, 2021, 99, 2554-2569.	0.9	1
478	Gene Expression Profiles Associated with Radio-Responsiveness in Locally Advanced Rectal Cancer. Biology, 2021, 10, 500.	1.3	9
479	Neutrophil Extracellular Traps in Colorectal Cancer Progression and Metastasis. International Journal of Molecular Sciences, 2021, 22, 7260.	1.8	36
480	Synthetic Lethality Screening Highlights Colorectal Cancer Vulnerability to Concomitant Blockade of NEDD8 and EGFR Pathways. Cancers, 2021, 13, 3805.	1.7	6
481	Identification of prognostic long intergenic nonâ€'coding RNAs as competing endogenous RNAs with KRAS mutations in colorectal cancer. Oncology Letters, 2021, 22, 717.	0.8	2
482	Predicting Colon Cancer-Specific Survival for the Asian Population Using National Cancer Registry Data from Taiwan. Annals of Surgical Oncology, 2022, 29, 853-863.	0.7	4
483	Genomic profiling of intestinal/mixedâ€'type superficial nonâ€'ampullary duodenal epithelial tumors. JGH Open, 2021, 5, 1071-1077.	0.7	2
484	Stromal Galectin-1 Promotes Colorectal Cancer Cancer-Initiating Cell Features and Disease Dissemination Through SOX9 and Î²-Catenin: Development of Niche-Based Biomarkers. Frontiers in Oncology, 2021, 11, 716055.	1.3	4
485	Personalising cancer medicine with prognostic markers. EBioMedicine, 2021, 72, 103577.	2.7	9
486	Metformin and colorectal cancer. Biocell, 2022, 46, 51-59.	0.4	1
487	Exosomal Circ_0125473 Drives Macrophages Polarization Toward M2 Through miR-5787/Wnt1/Î²-Catenin Signaling Pathway in Colorectal Cancer. SSRN Electronic Journal, 0, , .	0.4	0
488	Colorectal Cancer and Genetic Polymorphism in Key Regulatory Low Penetrance Genes. , 2021, , 119-164.		2
489	Colon Cancer Stem Cells. , 2012, , 155-179.		3
490	Molecular Parameters for Prognostic and Predictive Assessment in Colorectal Cancer. Updates in Surgery Series, 2013, , 41-62.	0.0	4
492	Epithelial Cell Signalling in Colorectal Cancer Metastasis. Cancer Metastasis - Biology and Treatment, 2010, , 205-241.	0.1	5
497	A Combined Proteomics and Mendelian Randomization Approach to Investigate the Effects of Aspirin-Targeted Proteins on Colorectal Cancer. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 564-575.	1.1	10
498	Consensus Pathways Implicated in Prognosis of Colorectal Cancer Identified Through Systematic Enrichment Analysis of Gene Expression Profiling Studies. PLoS ONE, 2011, 6, e18867.	1.1	31

#	ARTICLE	IF	CITATIONS
499	Tissue and Serum microRNAs in the KrasG12D Transgenic Animal Model and in Patients with Pancreatic Cancer. PLoS ONE, 2011, 6, e20687.	1.1	74
500	An RNA Interference Phenotypic Screen Identifies a Role for FGF Signals in Colon Cancer Progression. PLoS ONE, 2011, 6, e23381.	1.1	23
501	Transcriptome Profiling of the Cancer, Adjacent Non-Tumor and Distant Normal Tissues from a Colorectal Cancer Patient by Deep Sequencing. PLoS ONE, 2012, 7, e41001.	1.1	68
502	Berberine Inhibits Proliferation and Down-Regulates Epidermal Growth Factor Receptor through Activation of Cbl in Colon Tumor Cells. PLoS ONE, 2013, 8, e56666.	1.1	57
503	Anomalies in Network Bridges Involved in Bile Acid Metabolism Predict Outcomes of Colorectal Cancer Patients. PLoS ONE, 2014, 9, e107925.	1.1	4
504	Genetic Characteristics of Mitochondrial DNA Was Associated with Colorectal Carcinogenesis and Its Prognosis. PLoS ONE, 2015, 10, e0118612.	1.1	32
505	Canonical Wnt Signaling Drives Tumor-Like Lesions from Sox2-Positive Precursors of the Murine Olfactory Epithelium. PLoS ONE, 2016, 11, e0166690.	1.1	7
506	Overexpression of Rad51 Predicts Poor Prognosis in Colorectal Cancer: Our Experience with 54 Patients. PLoS ONE, 2017, 12, e0167868.	1.1	15
507	Histone Deacetylase-3/CAGE Axis Targets EGFR Signaling and Regulates the Response to Anti-Cancer Drugs. Molecules and Cells, 2016, 39, 229-241.	1.0	19
509	Oncogenic Ras triggers hyperproliferation and impairs polarized colonic morphogenesis by autocrine ErbB3 signaling. Oncotarget, 2016, 7, 53526-53539.	0.8	9
510	The clinical role of microRNA-21 as a promising biomarker in the diagnosis and prognosis of colorectal cancer: a systematic review and meta-analysis. Oncotarget, 2017, 8, 44893-44909.	0.8	82
511	Meta-analysis indicating that high ALCAM expression predicts poor prognosis in colorectal cancer. Oncotarget, 2017, 8, 48272-48281.	0.8	6
512	SNHG1 promotes cell proliferation by acting as a sponge of miR-145 in colorectal cancer. Oncotarget, 2018, 9, 2128-2139.	0.8	52
513	Advances in dynamic modeling of colorectal cancer signaling-network regions, a path toward targeted therapies. Oncotarget, 2015, 6, 5041-5058.	0.8	24
514	eIF4E binding protein 1 expression is associated with clinical survival outcomes in colorectal cancer. Oncotarget, 2015, 6, 24092-24104.	0.8	16
515	Loss of expression of the double strand break repair protein ATM is associated with worse prognosis in colorectal cancer and loss of Ku70 expression is associated with CIN. Oncotarget, 2012, 3, 1348-1355.	0.8	54
516	miR-143 or miR-145 overexpression increases cetuximab-mediated antibody-dependent cellular cytotoxicity in human colon cancer cells. Oncotarget, 2016, 7, 9368-9387.	0.8	42
517	Withaferin-A suppress AKT induced tumor growth in colorectal cancer cells. Oncotarget, 2016, 7, 13854-13864.	0.8	39

#	ARTICLE	IF	CITATIONS
518	MicroRNA-543 suppresses colorectal cancer growth and metastasis by targeting KRAS, MTA1 and HMGA2. Oncotarget, 2016, 7, 21825-21839.	0.8	87
519	UCN-01 enhances cytotoxicity of irinotecan in colorectal cancer stem-like cells by impairing DNA damage response. Oncotarget, 2016, 7, 44113-44128.	0.8	17
520	TES inhibits colorectal cancer progression through activation of p38. Oncotarget, 2016, 7, 45819-45836.	0.8	16
521	Neurochemical Markers in the Mammalian Brain: Structure, Roles in Synaptic Communication, and Pharmacological Relevance. Current Medicinal Chemistry, 2017, 24, 3077-3103.	1.2	14
522	GRP78 Regulates Apoptosis, Cell Survival and Proliferation in 5-Fluorouracil-resistant SNUC5 Colon Cancer Cells. Anticancer Research, 2017, 37, 4943-4951.	0.5	14
523	TP53 Gene Pro72Arg (rs1042522) Single Nucleotide Polymorphism as Not a Risk Factor for Colorectal Cancer in the Iranian Azari Population. Asian Pacific Journal of Cancer Prevention, 2017, 18, 3423-3427.	0.5	13
524	Teaching RNAseq at Undergraduate Institutions: A tutorial and R package from the Genome Consortium for Active Teaching. CourseSource, 0, 2, .	0.0	7
525	Association of overexpression of TIF1γ with colorectal carcinogenesis and advanced colorectal adenocarcinoma. World Journal of Gastroenterology, 2011, 17, 3994.	1.4	29
526	Input of microenvironmental regulation on colorectal cancer: Role of the CCN family. World Journal of Gastroenterology, 2014, 20, 6826.	1.4	18
527	Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years. World Journal of Gastroenterology, 2014, 20, 9775.	1.4	105
528	Detection of KRAS G12D in colorectal cancer stool by droplet digital PCR. World Journal of Gastroenterology, 2017, 23, 7087-7097.	1.4	12
529	Novel methylation gene panel in adjacent normal tissues predicts poor prognosis of colorectal cancer in Taiwan. World Journal of Gastroenterology, 2020, 26, 154-167.	1.4	3
530	Modeling Colorectal Cancer. Advances in Medical Technologies and Clinical Practice Book Series, 2013, , 53-75.	0.3	1
531	Expression level of long noncoding RNA NKILA-miR103-miR107 inflammatory axis and its clinical significance as potential biomarker in patients with colorectal cancer. Journal of Research in Medical Sciences, 2020, 25, 41.	0.4	12
532	Molecular approach to genetic and epigenetic pathogenesis of early-onset colorectal cancer. World Journal of Gastrointestinal Oncology, 2016, 8, 83.	0.8	23
533	Increasing the α 2, 6 Sialylation of Glycoproteins May Contribute to Metastatic Spread and Therapeutic Resistance in Colorectal Cancer. Gut and Liver, 2013, 7, 629-641.	1.4	98
534	Statin use is associated with a reduced incidence of colorectal cancer expressing SMAD4. British Journal of Cancer, 2022, 126, 297-301.	2.9	5
535	Aberrant expression of MYD88 via RNA‐controlling CNOT4 and EXOSC3 in colonic mucosa impacts generation of colonic cancer. Cancer Science, 2021, 112, 5100-5113.	1.7	5

#	ARTICLE	IF	CITATIONS
536	Chemoprevention. , 2011, , 209-226.		0
538	Clinical Applications of Systems Biology Approaches. , 2011, , 409-428.		0
541	Predictive Markers in Colon Cancer. , 2013, , 1-23.		0
542	Cancers of the Rectum and Anal Canal. Molecular Pathology Library, 2013, , 141-171.	0.1	1
543	Genetic and Epigenetic Interaction in the Development of Colorectal Cancers. , 2013, 03, .		0
544	A Single Nucleotide Polymorphism in the MGMT Gene is a Novel Prognostic Biomarker in Patients with Metastatic Colorectal Cancer. British Journal of Medicine and Medical Research, 2015, 5, 604-611.	0.2	0
546	Gastrointestinal Malignancy: Genetic Implications to Clinical Applications. Cancer Treatment and Research, 2016, 168, 393-479.	0.2	0
547	International scientific communications in the field of colorectal tumour markers. World Journal of Gastrointestinal Surgery, 2017, 9, 127.	0.8	0
548	Single Nucleotide Polymorphisms as Biomarkers for Drug Response and Toxicity in the Management of Colorectal Cancer. Journal of Pharmacogenomics & Pharmacoproteomics, 2018, 09, .	0.2	0
550	Pathology in Colorectal Malignancy. , 2020, , 73-96.		0
551	Applications in Biomedicine. , 2020, , 99-167.		0
552	Aberrant Partial Chromosomal Instability With Chemotherapeutically Resistant Metachronous Colorectal Cancer Following a Synchronous Primary Colorectal Cancer: A Case Report. Cureus, 2020, 12, e11308.	0.2	2
553	Primary vascular tumors of bone: a spectrum of entities?. International Journal of Clinical and Experimental Pathology, 2011, 4, 541-51.	0.5	32
556	LSF expression and its prognostic implication in colorectal cancer. International Journal of Clinical and Experimental Pathology, 2014, 7, 6024-31.	0.5	13
557	KRAS and PIK3CA mutation frequencies in patient-derived xenograft models of pancreatic and colorectal cancer are reflective of patient tumors and stable across passages. American Surgeon, 2014, 80, 873-7.	0.4	12
558	Expression of ITGB1 predicts prognosis in colorectal cancer: a large prospective study based on tissue microarray. International Journal of Clinical and Experimental Pathology, 2015, 8, 12802-10.	0.5	25
559	The potential for liquid biopsies in the precision medical treatment of breast cancer. Cancer Biology and Medicine, 2016, 13, 19-40.	1.4	12
560	Prognostic significance of EGFR and KRAS mutations in NSCLC patients with brain metastases treated with radiosurgery. Journal of Radiosurgery and SBRT, 2015, 3, 171-178.	0.2	2

#	ARTICLE	IF	CITATIONS
561	A genome-wide search for determinants of survival in 1926 patients with advanced colorectal cancer with follow-up in over 22,000 patients. European Journal of Cancer, 2021, 159, 247-258.	1.3	6
562	Targeted deep sequencing reveals APC mutations as predictors of overall survival in Chinese colorectal patients receiving adjuvant chemotherapy. Scandinavian Journal of Gastroenterology, 2022, , 1-8.	0.6	0
563	T7 Endonuclease I-mediated voltammetric detection of KRAS mutation coupled with horseradish peroxidase for signal amplification. Mikrochimica Acta, 2022, 189, 75.	2.5	5
564	Evaluation of methylated DCR1 as a biomarker for response to adjuvant irinotecan-based therapy in stage III colon cancer: cancer and leukaemia Group B 89803 (Alliance). Epigenetics, 2022, , 1-11.	1.3	0
566	Tumours of the Small and Large Bowel. , 0, , 285-296.		0
567	KRAS mutations and M2PK upregulation in stool samples from individuals with positive fecal occult blood tests screened for colorectal cancer. Tumori, 2014, 100, 122-7.	0.6	1
569	Multi-Size Deep Learning Based Preoperative Computed Tomography Signature for Prognosis Prediction of Colorectal Cancer. Frontiers in Genetics, 2022, 13, .	1.1	4
570	AIMP2-DX2 provides therapeutic interface to control KRAS-driven tumorigenesis. Nature Communications, 2022, 13, 2572.	5.8	3
571	A specific upregulated long noncoding RNA in colorectal cancer promotes cancer progression. JCI Insight, 2022, 7, .	2.3	3
572	FBXW7 and Its Downstream NOTCH Pathway Could be Potential Indicators of Organ-Free Metastasis in Colorectal Cancer. Frontiers in Oncology, 2022, 11, .	1.3	9
573	Genomic biomarkers to guide precision radiotherapy in prostate cancer. Prostate, 2022, 82, .	1.2	3
574	Stem Cell Theory of Cancer: Origin of Metastasis and Sub-clonality. Seminars in Diagnostic Pathology, 2023, 40, 63-68.	1.0	2
575	Hot-Spot-Specific Probe (HSSP) for Rapid and Accurate Detection of KRAS Mutations in Colorectal Cancer. Biosensors, 2022, 12, 597.	2.3	1
576	Checkpoint molecules on infiltrating immune cells in colorectal tumor microenvironment. Frontiers in Medicine, 0, 9, .	1.2	5
577	Chemically modified MIR143-3p exhibited anti-cancer effects by impairing the KRAS network in colorectal cancer cells. Molecular Therapy - Nucleic Acids, 2022, 30, 49-61.	2.3	6
578	Fusobacterium nucleatum, a key pathogenic factor and microbial biomarker for colorectal cancer. Trends in Microbiology, 2023, 31, 159-172.	3.5	52
579	Bowel cancer screening. Surgery, 2022, , .	0.1	0
580	Monogenic deficiency in murine intestinal Cdc42 leads to mucosal inflammation that induces crypt dysplasia. Genes and Diseases, 2024, 11, 413-429.	1.5	1

#	ARTICLE	IF	CITATIONS
581	Emerging Role of Neutrophil Extracellular Traps in Gastrointestinal Tumors: A Narrative Review. International Journal of Molecular Sciences, 2023, 24, 334.	1.8	2
582	Bioinformatic analysis of the obesity paradox and possible associated factors in colorectal cancer using TCGA cohorts. Journal of Cancer, 2023, 14, 379-392.	1.2	2
584	<scp>METTL14</scp> modulates glycolysis to inhibit colorectal tumorigenesis in p53â€wildâ€type cells. EMBO Reports, 2023, 24, .	2.0	7
586	Effect of Silibinin on the Expression of Mir-20b, Bcl2L11, and Erbb2 in Breast Cancer Cell Lines. Molecular Biotechnology, 0, , .	1.3	0
587	Application of nanotechnology in reversing therapeutic resistance and controlling metastasis of colorectal cancer. World Journal of Gastroenterology, 0, 29, 1911-1941.	1.4	0